Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group boosted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 111.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 156,874 shares of the company’s stock after acquiring an additional 82,601 shares during the quarter. Schroder Investment Management Group owned about 0.30% of Janux Therapeutics worth $8,236,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the fourth quarter worth $139,000. Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth $230,000. Legato Capital Management LLC acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth $347,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Janux Therapeutics in the third quarter valued at about $317,000. Finally, Virtu Financial LLC increased its stake in shares of Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after acquiring an additional 2,419 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares of the company’s stock, valued at $314,582,722.74. This trade represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 11,668 shares of company stock valued at $548,183 over the last quarter. Company insiders own 29.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JANX shares. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Finally, Scotiabank decreased their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $92.44.

Janux Therapeutics Trading Down 4.5 %

NASDAQ JANX opened at $25.77 on Friday. The business’s 50-day moving average price is $34.09 and its 200 day moving average price is $45.29. Janux Therapeutics, Inc. has a twelve month low of $24.30 and a twelve month high of $71.71. The company has a market capitalization of $1.52 billion, a PE ratio of -22.03 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.